Zenlabs ethica Ltd has announced the resignation of its Company Secretary & Compliance Officer, marking a key managerial personnel change at the pharmaceutical company. The resignation was communicated to BSE Limited on March 02, 2026, in compliance with regulatory disclosure requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Personnel Departure Details

Mr. Amit Kumar, holding membership number ACS 78790, has resigned from his position as Company Secretary & Compliance Officer due to personal reasons. The resignation follows proper regulatory procedures and timeline requirements as mandated under SEBI regulations.

Regulatory Compliance and Timeline

The resignation was submitted through a formal letter dated February 23, 2026, with Kumar being relieved from his responsibilities at the close of business hours on March 02, 2026. This represents a seven-day notice period from the date of resignation submission to the effective date of departure.

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026. The notification was signed by Sanjay Dhir, Whole-Time Director with DIN 02452461, ensuring proper authorization of the disclosure.

Board Recognition and Confirmation

The Board of Directors has placed on record its appreciation for the valuable services rendered by Mr. Amit Kumar during his tenure with the company. The departing officer has confirmed that there are no other material reasons for his resignation beyond those mentioned in his resignation letter.

The resignation represents a standard personnel change with proper regulatory compliance and documentation. The company has provided all required details as mandated under SEBI regulations, including the reason for change, date of cessation, and confirmation of no additional material reasons for the departure. The formal communication was addressed to the Corporate Relations Department of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Zenlabs ethica Ltd has received a GST demand notice from the Central Goods and Services Tax Division, marking a significant regulatory development for the pharmaceutical company. The notice, issued under Section 73 of the CGST Act, 2017, relates to alleged tax violations during the 2019-20 period.

GST Demand Notice Details

The demand notice, bearing Order No. 10/GST/SUPDT/DB.I/R.I/2024-25, was dated February 16, 2026, and received by the company on February 23, 2026. The notice was issued by the Superintendent, Range I, Central Goods and Services Tax Division-1, Derabassi, Government of Punjab.

Financial Impact Breakdown

The GST demand notice alleges multiple violations stemming from under-declaration of taxable turnover. The total financial impact comprises several components across different categories of alleged non-compliance.

Alleged Violations

The Central GST Division has identified several areas of non-compliance during the 2019-20 tax period. The primary allegation centers on under-declaration of taxable turnover, which has led to cascading effects across multiple tax compliance areas.

The specific violations alleged include:

• Short payment of tax liability due to under-declaration
• Claiming ineligible input tax credit
• Interest charges on late payment of taxes
• Penalty imposition under the prescribed provisions

Company Response and Impact Assessment

Zenlabs Ethica has indicated that the financial impact of the notice is limited to the extent of the demand, penalty, and interest levied. The company has stated there is no material impact on its financial operations or other business activities due to this notice.

The company plans to take appropriate action regarding the demand notice within the prescribed timeline as per regulatory requirements. This development has been disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders and the stock exchanges.